Result: Risk Minimisation Materials for medicines starting with the letter E
Effentora
Teva Pharma B.V.

About Effentora - Information for Healthcare Professionals
About Effentora - Information for Healthcare Professionals
For Healthcare Professionals

About Effentora - Information for Patents and Caregivers
About Effentora - Information for Patents and Caregivers

Effentora Treatment Diary
Effentora Treatment Diary
Elidel
Mylan

Elidel Educational brochure for HCPs
Important information on the appropriate use of Elidel for HCPs
For Healthcare Professionals
Eliquis
Bristol-Myers Squibb-Pfizer

Eliquis (apixaban) Healthcare Professional Risk Minimisation Material Website
This website is for healthcare professionals (HCPs) and is based on the paper and electronic version of the Eliquis (apixaban) Prescriber Guide. The website contains information for HCPs to be aware of before prescribing apixaban and in particular is aimed at increasing awareness about the potential risk of bleeding with apixaban. The website includes information on increased bleeding risks with apixaban, guidance on the use of apixaban in patients undergoing surgery and invasive procedures, therapy management, management of overdose and haemorrhage. The site can be viewed using Firefox, Google Chrome or recent versions of Internet Explorer.
For Healthcare Professionals

Eliquis (apixaban) Patient Alert Card
Patients prescribed Eliquis (apixaban) will receive a Patient Alert Card in the medication pack with the package leaflet. Please ensure you have read and understood the information in the card because it contains important safety information including the importance of taking apixaban regularly as instructed by the doctor, the main signs and symptoms of bleeding, and when to seek medical attention. Please carry the Patient Alert Card with you at all times and show it to every healthcare professional including pharmacists. Editorial updates were recently made to the card and the latest version of the card is dated January 2021. If you have lost the copy of the Patient Alert Card that is included in the medication pack, or it is damaged, please contact BMS Medical Information for a replacement copy (telephone: 0800 731 1736; e-mail: [email protected]).

Eliquis (apixaban) Prescriber Guide
This risk minimisation material is for Eliquis for all indications. Please ensure that you are familiar with this material before prescribing Eliquis as it contains important safety information on the potential risk of bleeding during treatment with Eliquis and provides guidance on how to manage that risk. Updates made to the Prescriber Guide in in May 2021 reflect changes to the Summary of Product Characteristics (SPC) for apixaban 2.5 mg and 5 mg tablets on ‘Patients with active cancer’. Other editorial changes were made including updates to the presentation of the Prescriber Guide. If you would like to obtain hard copies of the Eliquis Prescriber Guide and/or Patient Alert Card and/or SPCs, please contact Bristol-Myers Squibb Medical Information (telephone: 0800 731 1736; Email: [email protected]) with your specific request. Risk minimisation materials can only be delivered to UK registered healthcare premises.
For Healthcare Professionals
ELOINE
Bayer plc

CHCs - Checklist for Prescribers
Combined Hormonal Contraceptives - checklist for prescribers
For Healthcare Professionals

CHCs - Q&A on Important Info for Women
Combined hormonal contraceptives: Q&As about the important information for women.

CHCs - Risk of Blood Clots with CHCs
Important Information for women about risk of blood clots with combined hormonal contraceptives.
Elvanse
Takeda UK Ltd

Elvanse - Chart for ongoing monitoring of lisdexamfetamine therapy - HCP - Nov2017
Elvanse - Chart for ongoing monitoring of lisdexamfetamine therapy - HCP - Nov2017
For Healthcare Professionals

Elvanse - Checklist 1: lisdexamfetamine checklist before prescribing - HCP - Nov2017
Elvanse - Checklist 1: lisdexamfetamine checklist before prescribing - HCP - Nov2017
For Healthcare Professionals

Elvanse - Checklist 2: checklist for ongoing monitoring of lisdexamfetamine therapy - HCP - Nov2017
Elvanse - Checklist 2: checklist for ongoing monitoring of lisdexamfetamine therapy - HCP - Nov2017
For Healthcare Professionals

Elvanse - potential for non-medical use & diversion of prescription stimulant medications - Pt - Nov2017
Elvanse - potential for non-medical use & diversion of prescription stimulant medications - Pt - Nov2017

Elvanse Adult - Chart for ongoing monitoring of lisdexamfetamine therapy - HCP - Dec2016
Elvanse Adult - Chart for ongoing monitoring of lisdexamfetamine therapy - HCP - Dec2016
For Healthcare Professionals

Elvanse Adult - Checklist 1: lisdexamfetamine dimesylate checklist before prescribing - HCP - Dec2016
Elvanse Adult - Checklist 1: lisdexamfetamine dimesylate checklist before prescribing - HCP - Dec2016
For Healthcare Professionals

Elvanse Adult - Checklist 2: checklist for ongoing monitoring of lisdexamfetamine dimesylate therapy - HCP - Dec2016
Elvanse Adult - Checklist 2: checklist for ongoing monitoring of lisdexamfetamine dimesylate therapy - HCP - Dec2016
For Healthcare Professionals

Elvanse Adult - potential for non-medical use & diversion of prescription stimulant medications - Pt - Dec2016
Elvanse Adult - potential for non-medical use & diversion of prescription stimulant medications - Pt - Dec2016
Emerade
Bausch & Lomb U.K Limited

Emerade Expiry Reminder
Enter your pen expiry dates below and we will remind you to re-order your prescription 30 days before via email. Alternatively you can download a calendar reminder to save in your phone or computer calendar.

How to use Emerade instruction video
Demonstration video to show you how to use your Emerade autoinjector pen.
Emerres
Morningside Healthcare Ltd

Emerres 1.5mg - Patient Advice Leaflet
Patient leaflet explaining about what you may need to do and who you should contact if taking various other medication.

Emerres Una - Patient Advice Leaflet
Includes information for women that are taking other medicines and what you may need to do and who you may need to talk to.

Emerres Una - Patient Questionnaire Checklist
The following list of questions is designed to support you in determining whether Emerres Una is a suitable choice of emergency contraceptive for an individual patient following unprotected sexual intercourse or contraceptive failure.
For Healthcare Professionals
Emtricitabine+Tenofovir
Dr. Reddy's Laboratories (UK) Ltd

Emtricitabine/Tenofovir disoproxil Dr. Reddy's 200 mg/245 mg Film-Coated Tablets
Renal and bone effects risk minimisation material: Tenofovir disoproxil for children and adolescents with HIV-1
For Healthcare Professionals

Checklist for Prescribers v2 Tenofovir PrEP
Initiation of emtricitabine/tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP) Complete checklist at each visit and file in individuals medical record.
For Healthcare Professionals

Important Information about Emtricitabine/Tenofovir Disoproxil To Reduce The Risk Of Getting Human Immunodeficiency Virus (HIV) Infection
Information for individuals who have been prescribed emtricitabine/tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP)

Important Safety Information for prescribers v2 Tenofovir PrEP
Emtricitabine/ tenofovir disoproxil is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults at high risk. This indication is based on clinical trials in men who have sex with men (MSM) at high risk for HIV-1 infection and on men and women in heterosexual serodiscordant couples.
For Healthcare Professionals

Reminder Card v2 Tenofovir PrEP
You have been prescribed emtricitabine/ tenofovir disoproxil for PrEP (pre-exposure prophylaxis) to help reduce the risk of getting HIV-1 infection. For this medicine to work effectively it is important that you don’t miss doses. The recommended dose is one emtricitabine/ tenofovir disoproxil tablet each day. Take emtricitabine/ tenofovir disoproxil exactly as your doctor has told you.
Lupin Healthcare (UK) Ltd

Checklist for Prescribers
Initiation of emtricitabine/tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP)
For Healthcare Professionals

Important Information about Emticitabine/Tenofovir Disproxil
Information for individuals who have been prescribed emtricitabine/ tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP)
For Healthcare Professionals

Important Safety Information for Prescribers
For Prescribers About emtricitabine/ tenofovir disoproxil for a Pre-Exposure Prophylaxis (PrEP) Indication
For Healthcare Professionals

Reminder Card
EMTRICITABINE/ TENOFOVIR DISOPROXIL FOR PrEP REMINDER CARD
For Healthcare Professionals
Zentiva

CHECKLIST FOR PRESCRIBERS EMTRICITABINE/TENOFOVIR
Initiation of emtricitabine/tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP) Complete checklist at each visit and file in individual’s medical record.
For Healthcare Professionals

Important safety information for individuals to reduce the risk of getting HIV
This guide is intended for information only and should complement (not replace) the patient information leaflet supplied with your medicine. For a full list of side effects and other important information, please refer to the patient information leaflet provided in the box containing your medicine. Ask your healthcare provider if you have any questions.
For Healthcare Professionals

important safety information for prescribers v2 Tenofovir PrEP
Emtricitabine/ tenofovir disoproxil is indicated in combination with safer sex practices for preexposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults at high risk. This indication is based on clinical trials in men who have sex with men (MSM) at high risk for HIV-1 infection and on men and women in heterosexual serodiscordant couples.
For Healthcare Professionals

Reminder card v2 Tenofovir PrEP
You have been prescribed emtricitabine/ tenofovir disoproxil for PrEP (pre-exposure prophylaxis) to help reduce the risk of getting HIV-1 infection. For this medicine to work effectively it is important that you don’t miss doses. The recommended dose is one emtricitabine/ tenofovir disoproxil tablet each day. Take emtricitabine/ tenofovir disoproxil exactly as your doctor has told you.
For Healthcare Professionals

RENAL AND BONE EFFECTS RISK MINIMISATION MATERIAL:TENOFOVIR DISOPROXIL FOR CHILDREN AND ADOLESCENTS WITH HIV-1
Submission of Risk Minimisation Materials (coordinated by BGMA) to agency – minimising the risks of renal and bone effects for children and adolescents with HIV
Sandoz Limited

Checklist for prescribers of Emtricitabine/Tenofovir
Checklist for the initiation of Emtricitabine/Tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP)
For Healthcare Professionals

Important information about Emtricitabine/Tenofovir to reduce the risk of getting HIV infection
Information for individuals who have been prescribed Emtricitabine/Tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP)

Important safety information for prescribers of Emtricitabine/Tenofovir
Important safety information for prescribers of Emtricitabine/Tenofovir disoproxil for a Pre-Exposure Prophylaxis (PrEP) indication
For Healthcare Professionals

Patient Reminder Card
Patient Reminder Card: Emtricitabine/Tenofovir disoproxil for PrEP indication

Renal and bone effects risk minimisation material: Tenofovir disoproxil for children and adolescents with HIV-1
This brochure provides important advice on the management of potential renal and bone effects of tenofovir disoproxil in HIV-1 infected children and adolescents aged 2 to <18 years, and on the dosing recommendations for tenofovir disoproxil in this population.
For Healthcare Professionals
ADVANZ Pharma

Checklist for Prescribers v2 Tenofovir PrEP
Checklist for Prescribers v2 Tenofovir PrEP
For Healthcare Professionals

Important safety information for individuals using PrEP v2
Important safety information for individuals using PrEP v2
For Healthcare Professionals

Important safety information for prescribers v2 Tenofovir PrEP
Important safety information for prescribers v2 Tenofovir PrEP
For Healthcare Professionals


Tenofovir HBV indications materials for children and adolescents
Tenofovir HBV indications materials for children and adolescents
For Healthcare Professionals

Tenofovir HIV indications materials for children and adolescents
Tenofovir HIV indications materials for children and adolescents
For Healthcare Professionals
Mylan

Emtricitabine/Tenofovir disoproxil Checklist for Prescribers
Emtricitabine/Tenofovir disoproxil Checklist for Prescribers PrEP
For Healthcare Professionals

Emtricitabine/Tenofovir Disoproxil Patient Brochure
Patient Brochure for Emtricitabine/Tenofovir disoproxil for PrEP (pre-exposure prophylaxis)

Emtricitabine/Tenofovir Disoproxil Prescriber's Brochure
Important Safety Information for Prescribers About Emtricitabine/Tenofovir Disoproxil for a Pre-exposure Prophylaxis (PrEP) Indication
For Healthcare Professionals

Emtricitabine/Tenofovir HIV Paediactrics Brochure
Emtricitabine/Tenofovir HIV Paediactrics Brochure advice for HCPs
For Healthcare Professionals

Patient Reminder Card for Emtricitabine/Tenofovir Disoproxil
Patient Reminder Card for Emtricitabine/Tenofovir disoproxil for PrEP (pre-exposure prophylaxis).
Accord Healthcare Limited

HBV Indications - children and adolescents v4
This material provides important information and advice on the management of potential renal and bone effects of the use of tenofovir disoproxil in adolescents with chronic hepatitis B aged 12 to <18 years.

HIV Indications - children and adolescents
This material provides important information and advice on the management of potential renal and bone effects of the use of tenofovir disoproxil in adolescents infected with HIV-1 aged 2 to <18 years.

PrEP - Checklist for Prescribers v2
Checklist to be completed at each visit and filed in individuals medical records.

PrEP - Important safety information for individuals using v2
This guide is intended for information only to support the patient information leaflet, to provide the patient with additional information to reduce the risk of getting Human Immunodeficiency Virus (HIV) Infection.

PrEP - Important safety information for prescribers v2
This guide is to give the prescriber important safety information on Emtricitabine/Tenofovir to patients to reduce the risk of sexually acquired HIV-1 infections.

PrEP - Reminder card v2
This card is for each patient prescribed Emtricitabine/Tenofovir as a reminder to take the tablet each day.
Glenmark Pharmaceuticals Europe Ltd

Renal and Bone effects Risk Minimisation Material: Tenofovir Disoproxil for Children and Adolescents with HIV-1
HIV-1 Renal & bone effects education brochure - children and adolescent
For Healthcare Professionals
Enbrel
Pfizer Limited

Enbrel Patient Alert Card
Enbrel Patient Card
Enhertu
Daiichi Sankyo UK Limited

HCP Guide for Prevention of Product Confusion Medication Errors
This HCP guide is a condition of the Marketing Authorisation for Enhertu. It serves to minimise the important potential risk of medication error in addition to the SmPC. HCPs should read it before prescribing and administering Enhertu (trastuzumab deruxtecan). Risk of confusion between Enhertu (trastuzumab deruxtecan) and other trastuzumab-containing products including Kadcyla (trastuzumab emtansine).
For Healthcare Professionals

HCP Guide: Important Safety Information on ILD/Pneumonitis with treatment of Enhertu
This HCP guide is: - provided for HCPs to read before prescribing and administering Enhertu - an important tool to ensure the early recognition and diagnosis of ILD/pneumonitis, to allow prompt and appropriate treatment and minimise serious outcomes - a reminder to distribute a Patient Card to any patient receiving Enhertu treatment for the first time or if asked for a new copy
For Healthcare Professionals

Patient Card: Enhertu
- This Patient Card has been provided to you because your doctor has prescribed you Enhertu. - This Patient Card helps you to identify symptoms of lung problems that you may experience with Enhertu. - Read this information before you start receiving Enhertu and before each infusion. - You should keep this card with you at all times and show it to any doctor you consult (for example if your regular doctor is unavailable or if you are travelling).
Entyvio
Takeda UK Ltd

Entyvio (vedolizumab) HCP Educational Brochure
Information leaflet for HCPs Administering Entyvio
For Healthcare Professionals

Entyvio (vedolizumab) HCP Educational Brochure
Information leaflet for HCPs Administering Entyvio
For Healthcare Professionals

Entyvio (vedolizumab) Patient Alert Card
To be provided to patients receiving treatment with Entyvio by a HCP

Entyvio (vedolizumab) Patient Alert Card
To be provided to patients receiving treatment with Entyvio by a HCP
Envarsus
Chiesi Limited

Envarsus – prolonged-release tacrolimus tablets
Educational materials for the healthcare professional (doctor or pharmacist) Please read the full Summary of Product Characteristics before prescribing Envarsus
For Healthcare Professionals

Envarsus Patient Card
Envarsus Prolonged-release tacrolimus tablets Patient Card
For Healthcare Professionals
Epilim
SANOFI

Valproate- “White Box” Warning Labels
FOR DISPENSARY USE ONLY Warning Labels with Valproate Pregnancy Pictogram for Pharmacy to use with white box dispensing of these products. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]
For Healthcare Professionals

Valproate Annual Risk Acknowledgement Form
THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for use with girls and women of childbearing potential taking this product. It is to be completed with their specialist at least once a year to make sure they know and have understood all the risks related to the use of valproate during pregnancy and the need to avoid becoming pregnant while taking valproate.

Valproate- Healthcare professionals (HCPs) Guide Pregnancy prevention programme
Educational material for Healthcare Professionals (HCPs) about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]
For Healthcare Professionals

Valproate- Patient Card-Contraception and Pregnancy Prevention
Educational material for girls and women of childbearing potential about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

Valproate- Patient Guide- Pregnancy prevention programme
Educational material for girls and women of childbearing potential about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

Valproate- Poster- Dispensary- Pregnancy Prevention Programme
FOR DISPENSARY USE ONLY Dispensary A4 Poster for Pharmacy with key information about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]
For Healthcare Professionals
EpiPen
Mylan

EpiPen® Carry Card
Carry Card for EpiPen® patients

EpiPen® Expiry Alert Service
Expiry Alert Service using text or email for EpiPen® patients

EpiPen® Trainer Pen Order Form
Trainer Pen order form

EpiPen® Travel Certificate
Travel Certificate for those carrying EpiPen®

Guide to Using Your EpiPen® & Trainer Pen
Guide to Using Your EpiPen® & Trainer Pen leaflet

HCP Prescription Checklist for EpiPen and EpiPen Jr
Checklist for EpiPen and EpiPen Jr
For Healthcare Professionals
Episenta
Desitin Pharma Ltd

HCP Booklet - valproate use in female patients
Healthcare Professional (HCP) educational material, Pregnancy Prevention Programme
For Healthcare Professionals

Patient Card - valproate use in female patients
Patient Card for valproate in female patients - Contraception and Pregnancy Prevention

Patient Guide - valproate use in female patients
Patient Guide booklet for valproate in female patients - educational material, Pregnancy Prevention Programme

Valproate - Annual Risk Acknowledgement Form
Checklist for prescribers related to valproate use in female patients
For Healthcare Professionals

Valproate - Poster- Dispensary - Pregnancy Prevention Programme
Pharmacy poster reminding that valproate must be prescribed and dispensed according to the Valproate Pregnancy Prevention Programme.
For Healthcare Professionals

Epival
Gerot Lannach UK Limited

Valproate - “White Box” Warning Labels
FOR DISPENSARY USE ONLY Warning labels with valproate pregnancy pictogram for pharmacies to use with white box dispensing of these products. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

Valproate - Annual Risk Acknowledgement Form
THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for use with girls and women of childbearing potential taking this product. It is to be completed with their specialist at least once a year to make sure they know and have understood all the risks related to the use of valproate during pregnancy and the need to avoid becoming pregnant while taking valproate.

Valproate - Healthcare professionals (HCPs) Guide - Pregnancy Prevention Programme
Educational material for Healthcare Professionals (HCPs) about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]
For Healthcare Professionals

Valproate - Patient Card - Contraception and Pregnancy Prevention
Educational material for girls and women of childbearing potential about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

Valproate - Patient Guide - Pregnancy Prevention Programme
Educational material for girls and women of childbearing potential about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

Valproate - Poster - Dispensary - Pregnancy Prevention Programme
FOR DISPENSARY USE ONLY Dispensary A4 Poster for pharmacies with key information about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]
For Healthcare Professionals
Equasym
Takeda UK Ltd

Equasym - ADHD physicians guide to prescribing - July2021
Equasym - ADHD physicians guide to prescribing - July2021
For Healthcare Professionals

Equasym - Chart for ongoing monitoring during methylphenidate treatment - HCP - July2021
Equasym - Chart for ongoing monitoring during methylphenidate treatment - HCP - July2021
For Healthcare Professionals

Equasym - Checklist 1: checklist before prescribing - HCP - July2021
Equasym - Checklist 1: checklist before prescribing - HCP - July2021
For Healthcare Professionals

Equasym - Checklist 2: checklist for monitoring of ongoing therapy - HCP - July2021
Equasym - Checklist 2: checklist for monitoring of ongoing therapy - HCP - July2021
For Healthcare Professionals
Erivedge
Roche Products Limited

Erivedge (vismodegib) HCP Reminder Card
This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.
For Healthcare Professionals

Erivedge (vismodegib) Pharmacist Dispensing Checklist
This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.
For Healthcare Professionals

Erivedge (vismodegib) Pharmacists Confirmation of Role Form
This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.
For Healthcare Professionals

Erivedge (vismodegib) Pregnancy Prevention Programme Patient Booklet
This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.

Erivedge (vismodegib) Pregnancy Prevention Programme Patient Counselling Guidelines
This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.
For Healthcare Professionals

Erivedge (vismodegib) Prescriber Confirmation of Role Form
This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.
For Healthcare Professionals
Esbriet
Roche Products Limited

Esbriet (pirfenidone) Safety Checklist for Prescribing Physicians
This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan
For Healthcare Professionals
Esmya
Gedeon Richter (UK) Ltd

Pathologist's Guide - Esmya
Guide for pathologists dealing with gynaecological tissue which may have been exposed to Esmya (Ulipristal acetate) - revised Feb 2021.
For Healthcare Professionals

Patient Card - Esmya
This patient card will be present in the Esmya pack and is intended for the patient.

Physician's Guide to Prescribing - Esmya
Educational material for prescribers - revised Feb 2021
For Healthcare Professionals
Espranor
Martindale Pharma, an Ethypharm Group Company

Health Professionals’ Guide
Health Professionals’ Guide containing important information about Espranor
For Healthcare Professionals

Patients’ Guide - Information for HCP to give to patients prescribed Espranor
This is an Educational Material, for health professionals to give to patients prescribed Espranor
For Healthcare Professionals
evenity
UCB Pharma Limited

Evenity Patient Alert Card
This Patient alert card contains important safety information. The patient and, if appropriate their caregiver should be educated about treatment risks and provided with a Patient Alert Card.

Evenity Prescriber Guide
This guide is developed to increase awareness and educate prescribers about the important identified risks of serious cardiovascular events of MI and stroke and of hypocalcaemia and important potential risk of ONJ, and the appropriate prevention, early diagnosis and adequate management of these events.
For Healthcare Professionals
Evra
Gedeon Richter (UK) Ltd

Annex 2 CHC Prescriber Checklist
Please use this checklist in conjunction with the Summary of Product Characteristics during combined hormonal contraceptive (CHC) consultations.
For Healthcare Professionals

Annex 3 CHC User Card
Important Information for Women - Summary of risk of blood clots with combined hormonal contraception.

Annex 4 Important Information for Women
Leaflet with information on combined oral contraception to be given to the patient by the physician.
Exelon
Novartis Pharmaceuticals UK Ltd

Rivastigmine patch (Exelon/Prometax) - Instructions for use and patient diary - for patients
Instructions for use and a patient diary including medication record sheets for patients that have been prescribed Exelon Patch or Prometax Patch (rivastigmine transdermal system) to ensure the correct use of the patch.
Exembol
Mitsubishi Tanabe Pharma Europe Ltd.

Exembol (Argatroban Monohydrate) RMM - Dear HCP Letter
The Dear healthcare professional letter reflects the differences in administration and packaging between the new presentation - Exembol 1mg.ml Solution for Infusion and the original presentation - Exembol Multidose 100mg/ml concentrate for Solution for Infusion.
For Healthcare Professionals
Exjade
Novartis Pharmaceuticals UK Ltd

Exjade (deferasirox): Important information for patients about your treatment and possible side effects.
Please keep this document safe for future reference. This booklet is only intended for patients that have been prescribed deferasirox. It contains important information, including how to take deferasirox the right way, why monitoring your treatment is important, and which medicines you can take while on deferasirox.

Exjade Physician's Reference Checklist
Checklist for dosing and biological monitoring
For Healthcare Professionals

Important Information to Remember About Exjade (deferasirox) Treatment.
This booklet provides detailed information on posology and monitoring of patients on deferasirox, to minimise key adverse effects including medication errors during treatment.
For Healthcare Professionals
Eylea
Bayer plc

EYLEA BRVO Patient Guide
Your guide to Eylea - for the treatment of visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO)

EYLEA CNV Patient Guide
Your guide to Eylea - for the treatment of visual impairment due to myopic choroidal neovascularisation (myopic CNV)

EYLEA CRVO Patient Guide
Your guide to Eylea - for the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO)

EYLEA DMO Patient Guide
Your guide to Eylea - for the treatment of visual impairment due to diabetic macular oedema (DMO)

Eylea Prescriber Guide
Prescriber guide to intravitreal injections with Eylea.
For Healthcare Professionals

EYLEA WAMD Patient Guide
Your guide to Eylea - for the treatment of neovascular (wet) age-related macular degeneration (AMD).
Ezinelle
Mylan

Educational material for Pharmacists & Patients
Checklist for Pharmacists and Patients